JPMorgan raised the firm’s price target on Natera (NTRA) to $260 from $250 and keeps an Overweight rating on the shares. The firm updated models in the life science tools and diagnostics group.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $205 from $190 at Wells Fargo
- Natera price target raised to $270 from $230 at Barclays
- Natera, Medica Scientia Innovation Research to collaborate on MiRaDoR study
- Natera announces initial translational research data from Phase 3 study
- Natera files to sell 1.95M shares of common stock for holders